Adoptive T cell therapy for cancer in the clinic
J. Clin. Invest. Carl H. June, et al. 117:1466 doi:10.1172/JCI32446 [
Go to this article.]
Figure 1Schemes for adoptive transfer of autologous, vaccine-primed, in vitro–expanded T cells. Patients are primed with tumor vaccine followed by lymphocyte harvest. Autologous T cells are harvested from peripheral blood (i) or draining lymph nodes (ii), undergo polyclonal in vitro activation and expansion, and are reinfused after lymphodepleting chemotherapy. Antigen-specific immune function is measured after the administration of booster vaccines. (iii) TILs can be isolated from resected surgical specimens and expanded in vitro for adoptive transfer after lymphodepleting chemotherapy. Most adoptive transfer therapy approaches using TILs have involved the use of IL-2 infusion following T cell transfer in order to select tumor-specific T cells.
